Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation

Sanofi533 enrolled

Overview

The primary objective is to assess the efficacy a 20mg/day fixed dose of rimonabant versus placebo on abstinence from tobacco use in cigarette smoker. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

533

Conditions

Smoking Cessation

Interventions

rimonabantDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Smokers smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit * Motivated to quit with a score greater than or equal to 6 on the ten-point Motivation Scale Exclusion Criteria: * Non tobacco cigarettes consumption * Chronic use of marijuana * Pregnancy, breastfeeding * Any clinically significant disease that might interfere with the efficacy or safety evaluation of the study drug * Concomitant use of drugs as an aid to smoking cessation or that might induce weight change

Locations (1)

Sanofi-Aventis Administrative Office

Bridgewater, New Jersey, United States

Outcomes

Primary Outcomes

Prolonged abstinence from smoking during the last 4 weeks of treatment reported by the subject and confirmed by exhaled carbon monoxide (CO) and cotinine measurements

Secondary Outcomes

Efficacy: mean change of the total score of Questionnaire on Smoking Urges (QSU) brief scale, categorical change in body weight in subjects with Body Mass Index lower than 30 kg/m² at baseline who achieve prolonged abstinence

Safety data

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.